Gene therapy to lower eye pressure in glaucoma patients
Official title: Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment
Funded at Nanoscope Technologies, LLC · NIH-10695868 · Data updated 2026-11-12
This study is exploring a new gene therapy that could help people with glaucoma by improving how fluid drains from the eye, which may lower eye pressure and protect vision, and it will first be tested in lab cells and animals before moving on to humans.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanoscope Technologies, LLC NIH-funded |
| Lab location | 1 site (Arlington, United States) |
| Project start | September 30, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $875,350 |
| NIH project number | 5R44EY033626-02 |
| Project ID | NIH-10695868 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with glaucoma, particularly those who are elderly or have a family history of the condition.
✕Less likely to help
Patients with other forms of eye disease unrelated to glaucoma may not benefit from this research.
What this research studies
This research investigates a novel gene therapy approach to treat glaucoma by using engineered mechanosensitive channels to modulate pressure in the eye. The therapy aims to improve drainage of aqueous humor, which is often impaired in glaucoma patients, leading to elevated intraocular pressure (IOP) and potential vision loss. By delivering this therapy via a viral vector, the researchers hope to provide a long-lasting solution that minimizes side effects associated with current treatments. The study will involve testing the effectiveness of this therapy in both cultured cells and animal models before considering human applications.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for glaucoma patients, potentially preventing vision loss and improving quality of life.
How similar studies have gone: While gene therapy for glaucoma is a relatively novel approach, preliminary studies have shown promise in similar methodologies, indicating potential for success.
Where this research is happening
-
Nanoscope Technologies, LLC
Arlington, United States Active
Researchers
- Principal investigator: Dibas, Adnan Ismail — Nanoscope Technologies, LLC
- Study coordinator: Dibas, Adnan Ismail
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Comparing tube positions in glaucoma implants to protect corneal cells
This trial compares two tube placements for glaucoma drainage implants to see which better protects corneal cells and controls eye pressure in people with uncontrolled glaucoma.
-
Automated topographic test for glaucoma detection and progression
A new automated method uses topographic structure-function mapping to help diagnose glaucoma earlier and track its progression in patients.
-
Using AI on eye scans and genes to predict glaucoma risk
This project uses artificial intelligence on eye scans, vision tests, and genetic information to find people most likely to develop or have worsening glaucoma.
-
AI-based glaucoma screening in community health centers
A new, easy-to-use AI screening approach will be tested in federally funded health centers to help identify people at risk for glaucoma, especially in communities with higher risk.
-
Understanding how glaucoma genes control eye cell function
A long-term research project will study how genetic factors affect eye cells in adults with glaucoma to uncover new ideas for protecting vision.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.